Similar articles

• Treatment of biochemical recurrence of prostate cancer with granulocyte-macrophage colony-stimulating factor secreting, allogeneic, cellular immunotherapy.

  Urba WJ, Nemunaitis J, Marshall F, Smith DC, Hege KM, Ma J, Nguyen M, Small EJ. Urba WJ, et al. J Urol. 2008 Nov;180(5):2011-7; discussion 2017-8. doi: 10.1016/j.juro.2008.07.048. Epub 2008 Sep 17. J Urol. 2008. PMID: 18801509 Clinical Trial.
• Prostate-specific antigen (PSA) as a surrogate end point for survival in prostate cancer clinical trials.

  Collette L. Collette L. Eur Urol. 2008 Jan;53(1):6-9. doi: 10.1016/j.eururo.2007.08.041. Epub 2007 Aug 28. Eur Urol. 2008. PMID: 17764823 No abstract available.
• Significant prognostic factor of immunohistochemical HER-2 expression using initial prostate biopsy specimens with M1b prostate cancer.

  Tobiume M, Yamada Y, Nakamura K, Aoki S, Zennami K, Kato Y, Nishikawa G, Yokoi T, Honda N. Tobiume M, et al. Prostate. 2011 Mar 1;71(4):385-93. doi: 10.1002/pros.21252. Epub 2010 Sep 1. Prostate. 2011. PMID: 20812221
• Prostate cancer and PSA screening.

  Mameghan H. Mameghan H. Aust Fam Physician. 1999 Aug;28(8):777-81. Aust Fam Physician. 1999. PMID: 10495525 Review.
• [Place of surveillance in the treatment of localized prostate cancer].

  Ravery V, Boccon-Gibod L. Ravery V, et al. Prog Urol. 1999 Apr;9(2):225-30; discussion 229-30. Prog Urol. 1999. PMID: 10370945 Review. French.